Study design
MAY
This was a prospective, open-label, single-arm trial of DTG-TDF/XTC. This study was designed in a national context of use of efavirenz-containing triple antiretroviral regimen with possible changes in sleep quality. This regimen could particularly affect a population with high proportions of engagement in nightly sex work, such as TGW [Participants were recruited by outreach efforts of peer navigators, through testing campaigns conducted in places were transgender people gather or live, and through collaboration with a local transgender community-based organization. Eligible participants started ART and were followed for 48 weeks according to study protocol and procedures, between December, 2015 and May, 2019 (